A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Abbott Laboratories stock. As of the latest transaction made, Bridgewater Associates, LP holds 707,615 shares of ABT stock, worth $82.7 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
707,615
Previous 1,668,469 57.59%
Holding current value
$82.7 Million
Previous $173 Million 53.47%
% of portfolio
0.47%
Previous 0.92%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$100.07 - $118.13 $96.2 Million - $114 Million
-960,854 Reduced 57.59%
707,615 $80.7 Million
Q2 2024

Aug 14, 2024

SELL
$100.73 - $112.44 $6.82 Million - $7.61 Million
-67,688 Reduced 3.9%
1,668,469 $173 Million
Q1 2024

May 14, 2024

SELL
$109.52 - $120.96 $17.6 Million - $19.5 Million
-161,062 Reduced 8.49%
1,736,157 $197 Million
Q4 2023

Feb 14, 2024

SELL
$90.19 - $110.4 $16 Million - $19.6 Million
-177,244 Reduced 8.54%
1,897,219 $209 Million
Q3 2023

Nov 13, 2023

BUY
$95.53 - $114.62 $24 Million - $28.8 Million
251,477 Added 13.79%
2,074,463 $201 Million
Q2 2023

Aug 11, 2023

SELL
$100.78 - $112.29 $33.8 Million - $37.7 Million
-335,716 Reduced 15.55%
1,822,986 $199 Million
Q1 2023

May 12, 2023

SELL
$96.86 - $114.01 $6.01 Million - $7.08 Million
-62,089 Reduced 2.8%
2,158,702 $219 Million
Q4 2022

Feb 13, 2023

SELL
$95.06 - $111.52 $81.7 Million - $95.8 Million
-859,163 Reduced 27.9%
2,220,791 $244 Million
Q3 2022

Nov 10, 2022

BUY
$96.76 - $112.03 $27.1 Million - $31.4 Million
280,041 Added 10.0%
3,079,954 $298 Million
Q2 2022

Aug 11, 2022

SELL
$102.07 - $123.37 $25.1 Million - $30.3 Million
-245,517 Reduced 8.06%
2,799,913 $304 Million
Q1 2022

May 13, 2022

BUY
$114.02 - $139.04 $98.2 Million - $120 Million
861,685 Added 39.46%
3,045,430 $360 Million
Q4 2021

Feb 14, 2022

BUY
$115.53 - $141.46 $36.2 Million - $44.3 Million
313,352 Added 16.75%
2,183,745 $307 Million
Q3 2021

Nov 12, 2021

BUY
$116.66 - $129.06 $8.58 Million - $9.49 Million
73,563 Added 4.09%
1,870,393 $221 Million
Q2 2021

Aug 13, 2021

BUY
$105.79 - $124.53 $74.9 Million - $88.2 Million
708,381 Added 65.08%
1,796,830 $208 Million
Q1 2021

May 14, 2021

BUY
$108.84 - $128.23 $19.1 Million - $22.5 Million
175,523 Added 19.23%
1,088,449 $130 Million
Q4 2020

Feb 12, 2021

BUY
$105.0 - $114.42 $50.3 Million - $54.9 Million
479,463 Added 110.61%
912,926 $100 Million
Q3 2020

Nov 13, 2020

BUY
$91.64 - $111.29 $39.7 Million - $48.2 Million
433,463 New
433,463 $47.2 Million
Q2 2020

Aug 12, 2020

SELL
$76.57 - $98.0 $4.18 Million - $5.35 Million
-54,586 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$62.82 - $91.86 $3.43 Million - $5.01 Million
54,586 New
54,586 $4.31 Million
Q4 2017

Feb 13, 2018

SELL
$53.68 - $57.47 $409,202 - $438,093
-7,623 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$48.06 - $53.64 $366,361 - $408,897
7,623
7,623 $407,000

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $205B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.